SWOG researchers go digital at ASCO20 Virtual Scientific Program

May 18, 2020

PORTLAND, OR - Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

Due to the coronavirus pandemic, ASCO officials cancelled the annual Chicago meeting, the world's largest cancer research conference, and switched to an online format. About 2,215 abstracts will be presented over three days, and more than 3,400 abstracts were accepted for online publication. SWOG investigators will report on trials involving cancer treatment, prevention, and care strategies, as well as results of the first trial run through the NCI's National Clinical Trials Network (NCTN) to focus on financial toxicity - the severe financial and emotional toll exacted on patients by the costs of their cancer care.

Davendra Sohal, MD, MPH, an associate professor at the University of Cincinnati, will deliver an oral presentation on the primary findings from S1505, a randomized SWOG trial that compares two common chemotherapy regimens for early-stage pancreatic cancer, and tests chemotherapy prior to pancreatic cancer surgery.

In S1505, one group of pre-surgery patients received modified FOLFIRINOX, or mFOLFIRINOX, a combination of three chemotherapy drugs - fluorouracil, irinotecan, and oxaliplatin. The other group received a combination of gemcitabine and nab-paclitaxel. Sohal and his team found that chemotherapy treatment prior to surgery results in good outcomes - regardless of the drugs patients receive. Of the patients who received mFOLFIRINOX, 73 percent underwent surgery for their pancreatic cancer, while 70 percent of patients who received gemcitabine and nab-paclitaxel underwent surgery. Two years after treatment, 43 percent and 47 percent of all eligible patients who started treatment were alive in the mFOLFIRINOX and gemcitabine and nab-paclitaxel arms, respectively.

"We didn't find that one regimen was better than the other," Sohal said. "We did demonstrate that treating pancreatic cancer patients with chemotherapy before surgery can be done safely, and we established a benchmark with this approach, which can help us build future trials that can test other pancreatic cancer drugs and further refine pre-surgery chemotherapy treatment."

Here are other SWOG highlights of the ASCO20 Virtual Scientific Program: "I'm particularly impressed with this year's ASCO presentations," said SWOG Chair Charles D. Blanke, MD. "They spotlight some of our most ground-breaking clinical trials in recent years, and are a testament to the creativity, ambition, and tenacity of SWOG researchers."
SWOG Cancer Research Network is part of the National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program, and is part of the oldest and largest publicly-funded cancer research network in the nation. SWOG has nearly 12,000 members in 47 states and six foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org.


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.